Table 1

Infants born before 28 weeks’ gestational age (GA) during 2012–2018 in Norway

AllSurvived to PMA 40 weeks
AllReceived surfactant
nLISA (%)MV (%)Surf. (%)nMean GABPD-36 (%)BPD-40 (%)Mean (SD) MVnMean (SD) MV
Hospital 130725838925725.8552323 (34)22625 (35)
Hospital 225024859020225.9602216 (19)18417 (20)
Hospital 31634847313526.360169 (12)9411 (12)
Hospital 41154478839226.4421519 (39)7322 (42)
Hospital 597584747226.1542512 (16)4815 (18)
Hospital 6712185825426.2633117 (21)4220 (22)
Hospital 753870624526.74477 (12)2611 (14)
Hospital 8461589933226.1723433 (29)3033 (30)
Hospital 9311381712426.6381213 (19)1517 (22)
Hospital 10261585812126.333109 (16)168 (9)
6 smaller hospitals15773731226.7331711 (17)817 (18)
Total117420838394626.1552117 (26)76219 (28)
  • The first major column (all) describes the number treated at each hospital, and the proportions treated with LISA, MV and surfactant. The second major column describes infants who survived to 40 weeks’ PMA in terms of mean GA, proportions treated with supplemental oxygen or positive pressure respiratory support at PMA 36 (BPD-36) and 40 (BPD-40) weeks, and mean days and SD of MV (including infants who were not ventilated) of all and of those who received surfactant (LISA or after endotracheal intubation). Hospitals 1–7 were university hospitals. Data from the Norwegian Neonatal Network (n=1174 infants, 16 hospitals).

  • BPD-36 and BPD-40, supplemental oxygen or positive respiratory support at 36 and 40 weeks’ PMA; GA, gestational age (weeks); LISA, less invasive surfactant administration; mean (SD) MV, mean (SD) number of days on MV; MV, mechanical ventilation; n, number of infants; PMA, postmenstrual age (weeks); Surf., received surfactant.